- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Patent holdings for IPC class C07D 403/04
Total number of patents in this class: 7454
10-year publication summary
|
550
|
538
|
583
|
593
|
547
|
501
|
561
|
439
|
394
|
216
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Patent GmbH | 5731 |
146 |
| Bristol-myers Squibb Company | 4747 |
116 |
| Novartis AG | 10224 |
104 |
| Boehringer Ingelheim International GmbH | 4487 |
87 |
| Janssen Pharmaceutica N.V. | 3160 |
82 |
| Bayer AG | 3504 |
76 |
| Syngenta Crop Protection AG | 6707 |
74 |
| F. Hoffmann-La Roche AG | 7816 |
73 |
| Takeda Pharmaceutical Company Limited | 2713 |
68 |
| Merck Sharp & Dohme LLC | 3737 |
68 |
| Hoffmann-La Roche Inc. | 3804 |
66 |
| LG Chem, Ltd. | 17937 |
64 |
| AstraZeneca AB | 2820 |
64 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
60 |
| Rohm and Haas Electronic Materials Korea Ltd. | 332 |
59 |
| Genentech, Inc. | 4113 |
53 |
| Vertex Pharmaceuticals Incorporated | 1579 |
50 |
| Araxes Pharma LLC | 90 |
50 |
| BASF SE | 21318 |
48 |
| Incyte Corporation | 1066 |
45 |
| Other owners | 6001 |